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Abstract
POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes) is a rare paraneoplastic syn-
drome, caused by a plasma cell proliferative disorder, which is most commonly lambda restricted. The neurological hallmark, 
which forms one of the mandatory criteria for diagnosis, is a subacute onset demyelinating neuropathy, which can be rapidly 
disabling and painful. A number of multi-system features are also characteristic of this disorder, and certainly not restricted 
to those included in its acronym, which though limited, remains a useful and memorable name, helping distinguish POEMS 
syndrome from other paraproteinaemic neuropathies. The discovery of vascular endothelial growth factor (VEGF) in associa-
tion with POEMS syndrome has been extremely useful in aiding clinical diagnosis, and monitoring response to treatment, as 
well as helping understand the underlying mechanism of disease. Interestingly, however, treatment targeting VEGF has been 
disappointing, suggesting other disease mechanisms or inflammatory processes are also important. Current understanding 
of the pathogenesis of POEMS syndrome is outlined in detail in the accompanying article by Cerri et al. Here, we review 
the clinical features of POEMS syndrome, differential diagnosis and available treatment options, based on current literature.
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Introduction
The diagnosis of POEMS syndrome (polyneuropathy, orga-
nomegaly, endocrinopathy, M-protein, skin changes), based 
on the current Dispenzieri diagnostic criteria [1], requires 
the presence of both mandatory criteria (a polyneuropathy 
and a monoclonal plasma cell-proliferative disorder, almost 
always lambda restricted), and at least one major and one 
minor criterion (Table 1). POEMS syndrome differs from 
other paraproteinaemic and inflammatory neuropathies by its 
multi-organ involvement, thought to be caused by elevated 
pro-inflammatory and angiogenic cytokines. Multi-organ 
features extend beyond those included in its acronym, and 
not all features included in the acronym are required for 
diagnosis.
POEMS syndrome has a median age of onset in the sixth 
decade and a slight male preponderance [2]. Patients may 
present to one of a number of specialty clinics depending 
upon the initial symptoms. In the neurology clinic, patients 
typically describe a subacute, painful, distal neuropathy. If 
POEMS syndrome is suspected, a thorough systemic exami-
nation and timely organisation of relevant investigations are 
required to elicit all features that might aid diagnosis.
POEMS syndrome remains a rare disease and evidence 
for treatment is largely limited to retrospective cohort stud-
ies or case reports. Current treatment strategies all target the 
underlying plasma cell clone, with the exception of bevaci-
zumab, a monoclonal antibody targeting vascular endothelial 
growth factor (VEGF), which has had disappointing results. 
Management can be complicated, and POEMS syndrome 
can be fatal. With the right treatment, however, prognosis 
in many patients can be very good. Joint specialty clinics, 
usually staffed by haematologists and neurologists, can be 
valuable.
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Patients typically present with a subacute, distal, symmet-
rical, sensorimotor neuropathy, frequently painful, with 
allodynia and hyperpathia [3, 4]. Neuropathy is a common 
first clinical feature, and may be the only feature at first 
presentation [3, 5].
The lower limbs are affected earlier, and more severely, 
than the upper limbs [3, 6, 7]. Sensory symptoms usu-
ally precede motor symptoms [6]. Many patients quickly 
become wheelchair- or bed-bound due to weakness or 
pain. Clinical examination may reveal distal wasting, 
weakness and sensory loss affecting both large and small 
fibre sensory modalities [3].
Neurophysiology
Electrodiagnostic studies demonstrate a length-depend-
ent sensorimotor neuropathy, typically demyelinating, 
but with axonal degeneration [5, 7]. Conduction block is 
not usually present [5, 7]. In motor studies, reduction in 
motor conduction velocity (MCV) is an early sign, how-
ever, patients often already have significant axonal loss 
at presentation [7]. Sensory studies show reduction of, or 
often absent, sensory nerve action potentials [3, 5].
POEMS syndrome is distinguishable from other poly-
neuropathies on electrodiagnostic studies, with some over-
lap. In a study of 51 patients with POEMS syndrome, 70% 
met the European Federation of Neurological Societies and 
Peripheral Nerve Society criteria for definite chronic inflam-
matory demyelinating polyradiculoneuropathy (CIDP) [3]. 
Reduction in MCV is typically seen in similar proportions 
of patients with POEMS syndrome, CIDP and CMT1a [3, 
8]. However, while distal motor latencies tend to be pro-
longed in POEMS syndrome, they are less prolonged (and 
less often) than in CIDP or CMT1a [3, 8]. This is thought to 
indicate that slowing in POEMS syndrome is more promi-
nent in intermediate than distal segments, suggesting a 
potentially different disease pathogenesis from other inflam-
matory neuropathies [3, 5, 8, 9]. Conduction block is much 
more common in CIDP than POEMS syndrome [3, 8], and 
the discrepancy in severity between upper and lower limb 
axonal loss is more pronounced in POEMS syndrome [3, 8].
Neuropathology
Nerve biopsy can be used to support a diagnosis of POEMS 
syndrome, though in practice it is not essential, especially 
when other clinical and paraclinical findings already fulfil 
the diagnostic criteria. A number of pathological hallmarks 
for POEMS syndrome have been identified and are outlined 
in detail in the accompanying article by Cerri et al. Of all 
these features, the finding of regular uncompacted myelin 
lamellae (UML) in ≥ 1% of myelinated nerve fibres on elec-
tron microscopy, is thought to be highly specific for POEMS 
syndrome, though not 100% pathognomonic [10, 11].
Plasma cell dyscrasia
The plasma cell disorder underlying POEMS syndrome is 
typically IgA or IgG lambda restricted [12]. A paraprotein 
can be identified on serum protein electrophoresis and/or 
immunofixation in most patients, though in our own experi-
ence, and as noted in larger series [6, 12], some patients do 
not have a detectable paraprotein, even after serial testing. 
Demonstrating a plasma cell clone in these patients requires 
more extensive investigation.
Bone marrow biopsy
Patients with POEMS syndrome typically have few mono-
clonal plasma cells on iliac crest biopsies. In patients with 
localised disease, iliac crest biopsies can be normal [6, 12]. 
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In a study of 87 patients at the Mayo clinic, the median 
percentage of plasma cells in 67 pre-treatment bone mar-
row specimens was < 5%, with monoclonal plasma cells 
detected in two-thirds [12]. A typical finding in around half 
of pre-treatment specimens was the presence of histologi-
cally reactive-appearing lymphoid aggregates containing 
mixed B- and T-cells, with a plasma cell rim, most com-
monly lambda restricted (though some polytypic), thought 
to be unique to POEMS syndrome. Other frequent find-
ings included megakaryocyte hyperplasia and clustering, 
and atypical megakaryocyte appearances. Peripheral blood 
smears were normal.
Within osteosclerotic lesions, atypical plasma cells infil-
trate normal marrow with sclerosis of the bony lamellae [6]. 
Bone marrow aspirates from osteosclerotic lesions in two 
patients, by Kulkarni et al., revealed high levels of plasma-




Castleman’s disease (CD) is a rare heterogeneous lymph 
node disorder associated with high levels of interleukin-6 
(IL-6) [13]. Patients with CD can have neuropathy, with or 
without POEMS syndrome. In a minority, CD co-exists with 
neuropathy and a POEMS-like syndrome, without evidence 
of a monoclonal plasma cell disorder. These patients are 
excluded in the current diagnostic criteria for POEMS syn-
drome as they do not fulfil the mandatory criteria, and are 
felt to have a different disease/pathogenesis [1]. The type and 
severity of neuropathy differs depending upon the presence 
or absence of POEMS syndrome or CD. Patients with CD 
and neuropathy without POEMS syndrome typically have a 
mild, painless, distal sensory neuropathy, while patients with 
POEMS syndrome +/- CD typically have a painful senso-
rimotor neuropathy, most severe in those without CD [14].
In a study of 113 patients with biopsy confirmed CD 
treated between 1948 and 2002, 18% met criteria for POEMS 
syndrome [15]. Conversely, in a study of 87 patients with 
POEMS syndrome, 10 had CD and 5 had CD-like features 
on lymph node biopsy [12]. Patients with POEMS syndrome 
mostly exhibit HHV8 negative multicentric CD (MCD) [12, 
14, 15].
Overall survival is dependent on the presence or absence 
of CD, osteosclerotic lesions, and POEMS syndrome. 
In a Mayo clinic cohort, 5-year survival was very good 
in patients with unicentric CD (91%) or with MCD with 
osteosclerotic lesions and POEMS syndrome (90%), good 
in patients with MCD without POEMS syndrome (65%), 
and very poor in patients with MCD and POEMS syndrome 
without osteosclerotic bone lesions (27%) [15].
Sclerotic bone lesions
POEMS syndrome is associated with predominantly osteo-
sclerotic bone lesions, which can have mixed sclerotic-lytic 
components, and are also referred to as osteosclerotic mye-
loma. Lesions are often small, and multiple; in a study of 28 
patients undergoing chest and abdominal CT imaging, 68% 
of patients had multiple bone lesions, with 146 lesions iden-
tified in total, 97% reported as sclerotic, and 71% <10 mm 
in diameter [16]. Further imaging by 99mTc-HMDP bone 
scintigraphy enabled the pick-up of additional lesions in the 
skull and long bones, not in the field of view of CT, demon-
strating a benefit from imaging the complete skeleton, and 
of using dual imaging modalities. 18F-FDG PET/CT imag-
ing can also aid diagnosis and help identify lesions suitable 
for biopsy [17]. Lesions are commonly found in the pelvis, 
thoracic and lumbar vertebrae, and ribs, and also occur in 
the scapula, clavicle, sternum, skull and long bones [16, 17].
Vascular endothelial growth factor
Elevated VEGF is highly specific for POEMS syndrome 
(though not pathognomonic) and thought to be involved in 
the pathophysiology of systemic features including organo-
megaly and volume overload. Serum VEGF levels reflect 
disease activity, falling with treatment and rising with dis-
ease progression or relapse. Monitoring VEGF levels may 
be useful as a disease prognostic marker; Misawa et al. 
showed that reduction in serum VEGF levels to within the 
normal range by 6-months post-treatment was associated 
with longer relapse-free survival and better outcomes [18].
Minor criteria
Organomegaly
Clinical and radiological studies have shown that imaging, 
particularly CT, has higher sensitivity in identifying orga-
nomegaly compared to clinical examination [6, 19]. In a 
retrospective cohort of 29 patients diagnosed with POEMS 
syndrome in India between 1983 and 2009, all had orga-
nomegaly, including hepatomegaly (28/29), splenomegaly 
(21/29) and lymphadenopathy (7/29) [6]. The reporting of 
organomegaly is variable, however, and is lower in other 
cohorts [2].
Extravascular volume overload
Fluid overload may present peripherally or centrally. In a 
study of 91 patients undergoing 18FDG-PET CT, 46 had had 
serous cavity effusions, often affecting more than one cav-
ity [17]. The four most common sites were pleural, pelvic, 
pericardial and abdominal.
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Endocrinopathy
In a retrospective study of 64 patients with POEMS syn-
drome, 84% had endocrinopathy, 54% of whom had mul-
tiple endocrinopathies [20]. Hypogonadism was common-
est, affecting 79% of men. Other endocrine abnormalities 
described include thyroid dysfunction, abnormal calcium 
metabolism, glucose intolerance, diabetes, hyperprol-
actinemia, gynaecomastia, and less commonly adrenal 
insufficiency [20–22]. For diagnostic purposes, diabetes 
and thyroid disease alone are insufficient evidence of endo-
crinopathy, given the high incidence of both conditions sepa-
rately in the general adult population [1].
Skin changes
Skin changes are reported in as many as 90–100% of patients 
[6, 23, 24]. In a study of 107 patients with POEMS syn-
drome, patients had an average of 3 types of skin changes 
[23]. Hyperpigmentation and haemangiomas are the com-
monest findings [23, 24]. Other skin changes include skin 
thickening, hypertrichosis, acquired facial lipoatrophy, and 
infiltrated livedo reticularis with necrosis [23, 24]. Vascular-
type skin changes can include acrocyanosis, flushing, rubor, 
hyperaemia and Raynaud’s phenomenon [23, 24]. Nail 
changes include leukonychia and clubbing. Skin ulceration 
related to calciphylaxis can occur [25]. There is a significant 
association between the presence of skin changes and abnor-
mal pulmonary function tests, suggesting these patients be 
meticulously screened for respiratory complications [23].
Papilloedema
Optic disc swelling is often visible on bedside direct oph-
thalmoscopy, with detection aided by formal ophthalmology 
assessment and optical coherence tomography (OCT). In a 
retrospective study of 33 patients, 52% had bilateral disc 
swelling [26]. In some patients with disc swelling, raised 
CSF opening pressures have been described, though this is 
unlikely to be the only causative factor [26]. Elevated CSF 
protein, often linked to optic disc swelling in other inflam-
matory neuropathies, is present in POEMS syndrome [6]. 
Increased vascular permeability secondary to elevated 
VEGF may also be important. In a study of 17 patients with 
POEMS syndrome, serum VEGF concentrations were sig-
nificantly higher in patients with disc swelling compared to 
those without, and there was a positive correlation between 
serum VEGF levels and peripapillary retinal thickness on 
OCT [27]. None of the studied patients had elevated CSF 
opening pressures. Improvement of disc swelling has been 
shown to correlate with fall in VEGF concentrations [26].
Thrombocytosis and Polycythaemia
Thrombcytosis and polycythaemia commonly occur, how-
ever, testing for JAK2 mutation is typically negative [12].
Other described associations
Pulmonary symptoms
Pulmonary hypertension (PH) was found in 27% of a cohort 
of 154 patients with POEMS syndrome [28]. Unlike with 
primary PH, PH in POEMS syndrome tends to follow a less 
progressive, less severe course, and improve with treatment 
[28, 29]. In a different cohort, 28% of 137 patients had chest 
symptoms within 2 years of diagnosis [30]. The presence 
of respiratory muscle weakness is associated with a poorer 
survival outcome [30].
CNS involvement
In a study of 11 patients with POEMS syndrome, 9 had 
asymptomatic cranial pachymeningeal thickening on gad-
olinium-enhanced MRI [31]. Meningeal biopsy in two 
patients showed meningothelial cell proliferation with vas-
cular changes including neovascularisation, and narrowing/
occlusion of arterioles due to thickening of the media and 
endothelial hyperplasia. The role of VEGF was suggested 
by immunohistochemical staining for VEGF and VEGFR2.
Arterial vascular disease
Cardio- and cerebrovascular risk may be increased in 
POEMS syndrome. In a cohort of 90 patients, the estimated 
5-year ischaemic stroke risk was 13.4% [32]. Risk factors 
included degree of thrombocytosis on presentation and pres-
ence of bone marrow plasmacytosis. There were no cases 
of stroke in patients with treated POEMS syndrome and the 
authors suggested that treating the underlying syndrome was 
probably the best mechanism for reducing arterial risk.
Renal disease
Renal dysfunction has been documented to varying degrees. 
In a retrospective study of 299 patients with POEMS syn-
drome from China, 67 had renal impairment, mostly of 
moderate degree [33]. Microhaematuria and significant 
proteinuria were present in 29 and 17 patients, respectively. 
In other cohorts, the incidence of renal dysfunction is lower 
[1]. In the Chinese cohort, renal function improved with 
treatment in 66%. Early death and reduced overall survival 
were significantly likelier in patients who had severe renal 
dysfunction (estimated glomerular filtration rate < 30 ml/
min/1.73 m2) at baseline. Pathological findings on renal 
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biopsy, presumably secondary to the effects of VEGF and 
pro-inflammatory cytokines, include glomerular enlarge-
ment, with endothelial and mesangial cell proliferation and 
small artery vasculopathy [33, 34].
Patient evaluation and investigations
When POEMS syndrome is suspected, a detailed history and 
systems examination are essential. Recommended investiga-
tions are listed in Table 2. CSF examination usually reveals 
an elevated protein in the range of 1–2 g/L but a normal cell 
count [6].
Differential diagnosis
Chronic inflammatory demyelinating 
polyradiculoneuropathy
CIDP is an inflammatory, proximal and distal sensory-
motor neuropathy, with demyelinating features. Differences 
between CIDP and POEMS syndrome are listed in Table 3 
[3]. Unlike POEMS syndrome, CIDP usually responds well 
to monotherapy with intravenous immunoglobulin (IVIg) 
or steroids [35].
Monoclonal gammopathy of undetermined significance 
(MGUS)
MGUS is a pre-malignant plasma cell disorder, with IgM, 
non-IgM or light chain subgroups, which can transform into 
Waldenstrom’s macroglobulinaemia (WM), myeloma or AL 
amyloidosis [38]. There is a male predominance, and age 
of onset is typically higher than for POEMS syndrome [9]. 
Neuropathy is not required for diagnosis. Unlike POEMS 
syndrome, neuropathy, when present, is mostly associ-
ated with IgM paraproteins, usually IgM kappa [9] and 
many patients have antibodies targeting myelin-associated 
glycoprotein (MAG). The neuropathy in these patients is 
clinically different from POEMS syndrome: typically sen-
sory and painless, often with sensory ataxia and tremor 
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Table 3  POEMS vs CIDP [3, 8, 36, 37]
POEMS CIDP
Clinical findings Distal and proximal sensory and motor neuropathy Distal and proximal sensory and motor neuropathy
Often painful Painless
Neurophysiology Demyelinating polyradiculoneuropathy with 
axonal loss
Demyelinating polyradiculoneuropathy
Distal motor latency Prolonged More prolonged than POEMS
Conduction velocities Decreased (demyelinating range) Similarly decreased (demyelinating range)
Compound muscle action potentials Significantly attenuated, often absent Less severely attenuated
Lower limb vs upper limb discrepancy Significantly worse in lower limbs compared to 
upper limbs
Less discrepancy between upper and lower limbs
Distribution Intermediate nerve segments most affected Proximal and terminal nerve segments most 
affected
Neuropathology More severe axonal loss
Diffuse loss of myelinated fibres Multifocal loss of myelinated fibres
Degree of epineurial inflammation Endoneurial mononuclear cell infiltration and 
degree of epineurial inflammation
Epineurial vascular proliferation
Uncompacted myelin lamellae > 1% Onion bulb formation
Biomarkers Elevated VEGF Antibodies to paranodal proteins and gangliosides 
in a minority of cases
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[39]. Progression is slow, and neuropathy can be mild 
for many years. A watch-and-wait approach is commonly 
adopted, with decision to treat based on severity and rate 
of progression.
Waldenstroms macroglobulinaemia (WM)
WM is a malignant plasma cell dyscrasia, with an IgM 
paraprotein and > 10% infiltration of lymphoplasmacytic 
cells in the bone marrow [40]. It is usually indolent but can 
transform into a high-grade lymphoma. Like MGUS, there 
is a male predominance, and age of onset is usually older 
than POEMS syndrome. Around half of patients may have 
a symptomatic neuropathy, typically a distal sensory neu-
ropathy, clinically similar to MGUS, but with more axonal 
features on electrodiagnostic testing [41, 42]. Systemic 
symptoms can occur due to very high paraprotein levels 
and associated hyperviscosity. Systemic signs in WM can 
include hepatosplenomegaly, lymphadenopathy and anae-
mia. Treatment involves a rituximab-based chemotherapy 
regime, monitoring for hyperviscosity, and supportive treat-
ment [40, 43].
Myeloma
Myeloma is a malignant plasma cell disorder of bone mar-
row, causing osteolytic bone lesions and end-organ damage 
including anaemia, hypercalcaemia and renal failure [44]. 
The percentage of malignant plasma cells in bone marrow is 
much higher than in POEMS syndrome. Neuropathy attrib-
utable to disease is less common in myeloma than MGUS 
and WM and may often be attributable to chemotherapy 
rather than the disease process. Neuropathy is typically 
axonal but more heterogeneous than in MGUS, WM or 
POEMS syndrome. Treatment strategies target the plasma 
cell clone [44]. Most of the treatments for POEMS syndrome 
were first used in myeloma.
Immunoglobulin light chain (AL) amyloidosis
AL amyloidosis is an acquired disorder caused by monoclo-
nal, non-malignant plasma cells producing immunoglobulin 
light chains, most often lambda, which misfold into insolu-
ble beta-pleated sheets and deposit in the tissues [45]. His-
topathological identification of amyloid is achieved using 
Congo red staining with apple-green birefringence under 
polarised light. Like POEMS syndrome, AL amyloidosis has 
a number of characteristic systemic complications, though 
these are secondary to AL amyloid deposition. The compli-
cations include cardiomyopathy, hepatomegaly, nephrotic 
syndrome, fatigue and weight loss. Around a quarter of 
patients have polyneuropathy, which is typically painful like 
in POEMS [46]. In contrast, however, amyloid neuropathies 
are usually axonal and feature prominent autonomic involve-
ment [46]. Amyloid is characteristically absent in nerve and 
bone marrow biopsies in patients with POEMS syndrome 
[6]. The prognosis of AL amyloidosis without treatment is 
poor, especially in patients with cardiac involvement [45]. 
Treatment options are similar to POEMS syndrome, and 
include autologous stem cell transplant (ASCT) or chemo-
therapy [45, 47].
CANOMAD
Chronic Ataxic Neuropathy with Ophthalmoplegia, M-pro-
tein, Cold Agglutinins and Disialosyl antibodies (CANO-
MAD), is an antibody-associated neuropathy, caused by IgM 
antibodies targeting disialylated and polysialylated ganglio-
sides, including GD1b, GD3, GT1b and GQ1b [48]. Light 
chains may be kappa or lambda restricted or both [48]. The 
origin of the IgM antibodies is unclear; only some cases 
are reported to have an underlying plasma cell dyscrasia. 
Clonal B-cell infiltration in cranial and peripheral nerves and 
nerve roots has been described in one case [49]. Similar to 
POEMS syndrome, there is a male predominance and age of 
onset is typically in the 6th decade [48]. The neuropathy is 
often severe, but tends to be more slowly progressive than in 
POEMS syndrome, and predominantly sensory, often with a 
disabling sensory ataxia, and either demyelinating or axonal 
features on electrodiagnostic testing [48, 50].
Management
Evidence for treatment in POEMS syndrome is largely 
limited to retrospective cohort studies, with only one ran-
domised controlled trial (RCT) to date [51, 52]. IVIg or 
steroid monotherapy, commonly used in other inflammatory 
neuropathies, does not produce lasting benefit.
The current suggested treatment algorithm recommends 
localised radiotherapy for patients with localised disease, 
defined as up to 3 discrete bone lesions and no evidence of 
clonal plasma cells on iliac crest biopsy, or systemic treat-
ment in patients with diffuse disease, defined as > 3 bone 
lesions or clonal plasma cells on iliac crest biopsy [53]. 
Systemic treatment options include ASCT or chemother-
apy. Supportive treatment for neurological disability and 
systemic symptoms should also be considered [52, 53].
Radiotherapy
In a retrospective study of 146 patients treated at the Mayo 
clinic, 38 patients received radiotherapy as a first defini-
tive treatment for POEMS syndrome [54]. 54/66 of identi-
fied bone lesions were irradiated. Overall survival was 97% 
at 4 years, including patients requiring salvage therapy, 
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suggesting that even in patients where radiotherapy fails to 
prevent progression, trialling it first line may not negatively 
affect survival, and may prevent unnecessary systemic ther-
apy in responders. Response to treatment was mixed: event 
free survival was 52% at 4 years, 47% had clinical improve-
ment, and 48% required salvage treatment for poor response, 
progression or relapse. Patients with better haematological 
responses had lower risk of treatment failure. A retrospec-
tive study of 33 patients, treated in Seoul, also showed that 
radiotherapy was effective in improving clinical symptoms 
of POEMS syndrome in some patients, either alone or in 
combination with chemotherapy [55].
Alkylating chemotherapy agents
Melphalan can be effective with or without ASCT. In a sin-
gle centre prospective study of 31 patients using a 12-cycle 
treatment regime of melphalan and dexamethasone, com-
plete and partial haematological responses were achieved 
in 38.7% and 41.9% patients, respectively [56]. All had 
improvement in neurological symptoms. There were no 
treatment-related deaths. It was suggested that melphalan 
with dexamethasone was safe and effective, without the 
cost and treatment-related morbidity of ASCT, but longer 
term conclusions were limited by the short follow-up period 
(median 21 months).
Autologous stem cell transplant
Two large retrospective cohort studies support the use of 
ASCT in POEMS syndrome [57, 58]. Further studies are 
needed to compare relative risks and benefits of ASCT to 
other systemic treatments [57]. Though modifications to the 
process of ASCT have been made, significant risks remain, 
including engraftment syndrome, chemotherapy-associated 
risks, graft failure, pancytopaenia, serious infection, and 
death.
The largest cohorts receiving ASCT, from Europe (127 
patients) and the Mayo clinic (59 patients), reported a simi-
lar 5-year progression free survival of 74% and 75%, with 
patients followed up for a median 48 months and 45 months, 
respectively [57, 58]. Early responses included improvement 
in VEGF levels and systemic features such as volume over-
load [57]. In patients who progressed in the Mayo group, 
median time to progression was 43 months. Most relapses 
were radiological or VEGF-related, without clinical symp-
toms. Patients who progressed were still felt to have ben-
efitted from ASCT, and most responded well to second line 
therapy or observation. There were 13 and 3 deaths in the 
European and Mayo cohorts, respectively.
Neurological symptoms have been shown to improve 
post-ASCT. In a study of 60 patients followed up over a 
median 61 months, wheelchair use improved from 45 to 0% 
post-transplant and there was a reduction in the number of 
patients requiring walking aids and ankle–foot orthoses [59].
Thalidomide and lenalidomide
In the first RCT in POEMS syndrome, 25 patients eligi-
ble for systemic therapy but not ASCT, were randomised 
to either thalidomide + dexamethasone or placebo + dexa-
methasone for 24 weeks, before proceeding to a 48-month 
open-label safety study where all patients received thalido-
mide [51]. At 24-weeks, reduction rate of VEGF (the pri-
mary endpoint) was significantly greater in the treatment 
group. Motor outcome and two SF-36 quality of life scores 
were also significantly improved in the treatment groups, but 
other secondary outcome measures were not. A new sensory 
neuropathy was found in 23% of patients in the open-label 
group, likely thalidomide-related, however, overall nerve 
function, particularly motor function, improved. Mild brady-
cardia was common. Overall, despite the short trial period, 
it was concluded that thalidomide was a safe and effective 
treatment for POEMS syndrome.
Lenalidomide is structurally similar to thalidomide, but 
less neurotoxic. Two recent prospective studies, a number of 
small retrospective studies and a pooled analysis study have 
all shown it to be effective in POEMS syndrome, as either 
first- or second-line therapy [60–65].
Bortezomib
Bortezomib (Velcade) is a reversible proteosome inhibitor 
and approved by NICE for use with dexamathasone ± tha-
lidomide in myeloma and untreated mantle cell lymphoma. 
He et al. studied 20 patients, newly diagnosed with POEMS 
syndrome between Dec 2014 and May 2016, given 3–6 
cycles of induction therapy with reduced dose bortezomib, 
cyclophosphamide and dexamethasone [66]. Of those whose 
haematological response could be assessed, 7 showed com-
plete response, 6 partial response and 4 had stable disease. 
Despite concerns about bortezomib causing peripheral neu-
ropathy, no patient had worsening neurology and 19/20 had 
improvement in ONLS (Overall Neuropathy Limitations 
Scale) of at least 1 point. Systemic features also improved. 
No deaths or disease progression were seen during the fol-
low-up period, though limited to 11 months.
Therapies targeting VEGF
Bevacizumab is a monoclonal antibody targeting VEGF. 
A number of small studies and case reports have shown 
mixed results with bevacizumab, including treatment failure 
(except VEGF response), and worsening of disease leading 
to death [67–70]. Some case studies have shown benefit, 
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though these have been limited by short or unclear follow-
up periods, and bevacizumab has been used following, or 
in addition to other treatments including cyclophosphamide 
with dexamethasone [68, 71]. A small number of studies 
have suggested that short-term use of bevacizumab may be 
helpful as a bridge to definitive treatment such as ASCT, 
either alone or with other treatment such as thalidomide [72, 
73]. At this stage, the role of bevacizumab is unclear, and 
better understanding of the pathophysiology of POEMS syn-
drome is required before it can be recommended.
Follow‑up and outcomes
Post-treatment, prognosis in POEMS syndrome is good; in 
a study of 291 patients treated at the Mayo clinic between 
1974 and 2014, 10-year overall survival was 62%, with 
younger age, albumin > 3.2 g/dL and complete haematologi-
cal response to treatment all associated with better outcomes 
[74]. In an overlapping cohort, 5-year progression-free sur-
vival was 58%, with failure to achieve complete haematolog-
ical response after first-line treatment the main predictor of 
relapse or progression [75]. Even in patients who relapsed, 
however, prognosis was good: 92% of patients responded 
to second line treatment, and most who relapsed again 
responded to further treatment. Given the risk of relapse, 
close follow-up of clinical, radiological and biochemical 
parameters, is essential.
Conclusions
POEMS syndrome is a rare, but treatable cause of neuropa-
thy. Further work is required to establish its exact underlying 
pathophysiology. Current treatment approaches afford good 
prognosis. Moving forward, randomised-controlled studies, 
though difficult given the rarity of POEMS syndrome, and 
the development of prognostic tools, will be important in 
establishing individualised approaches to patient care.
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